Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitreocare is an oral dietary supplement developed to support the physiological health and structural integrity of the vitreous humor in the eye. It is primarily indicated for individuals experiencing vitreous degeneration or floaters, a condition known as myodesopsia. The formulation typically consists of a synergistic blend of electrolytes (potassium and magnesium), antioxidants (Vitamin C, Vitamin E, and grape seed extract), and structural components (hydrolyzed collagen and hyaluronic acid). These ingredients work together to maintain the hydration of the vitreous gel, protect the ocular tissues from oxidative stress, and reinforce the collagenous framework of the vitreous body. By addressing these factors, Vitreocare aims to reduce the perception of floaters caused by the aggregation of collagen fibers and the liquefaction of the vitreous humor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vitreocare.